Get the Stockscreener App
185.95
0.31%
0.33
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $185.95, with a volume of 4.02M.
It is up +0.31% in the last 24 hours and down -4.56% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$185.62
Open:
$185
24h Volume:
4.02M
Relative Volume:
0.53
Market Cap:
$328.20B
Revenue:
$57.37B
Net Income/Loss:
$4.20B
P/E Ratio:
79.13
EPS:
2.35
Net Cash Flow:
$15.39B
1W Performance:
+1.60%
1M Performance:
-4.56%
6M Performance:
+1.79%
1Y Performance:
+19.12%
1-Day Range:
$183.01
$186.69
1-Week Range:
$182.37
$186.75
52-Week Range:
$156.20
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
185.80 | 322.44B | 57.37B | 4.20B | 15.39B | 2.35 |
|
LLY
Lilly Eli Co
|
740.36 | 642.06B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.04 | 367.19B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVS
Novartis Ag Adr
|
115.66 | 222.20B | 53.22B | 12.86B | 14.85B | 6.39 |
|
NVO
Novo Nordisk Adr
|
71.40 | 302.90B | 43.59B | 15.04B | 10.74B | 3.3766 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV)June 3, 2025 Deadline to Join – Contact Levi & Korsinsky - TradingView
AbbVie’s ADC win shows how pharma can break through in solid tumors - Pharma Voice
AbbVie (ABBV) Stock Dips in Morning Trade: What Key Numbers Reveal - Daily Chhattisgarh News
AbbVie announces multi-year partnership with the Chicago Cubs - TipRanks
Analyst recommendations: AbbVie, Emerson Electric, Marriott International, Zscaler, and Monster Beverage… - marketscreener.com
AbbVie (ABBV) Partners with Chicago Cubs for Cancer Awareness In - GuruFocus
AbbVie Partners with Chicago Cubs on "Striking Out Cancer" | ABBV Stock News - GuruFocus
AbbVie Partners with Chicago Cubs on "Striking Out Cancer" - PR Newswire
Berenberg Adjusts Price Target on AbbVie to $170 From $195, Maintains Hold Rating - marketscreener.com
The Zacks Analyst Blog Highlights Berkshire Hathaway, AbbVie, Intuitive Surgical, Hamilton Beach Brands and AXIL Brands - TradingView
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. LawsuitABBV - marketscreener.com
How Is AbbVie's Stock Performance Compared To Other Pharmaceuticals Stocks? - Barchart.com
Top Research Reports for Berkshire Hathaway, AbbVie & Intuitive Surgical - MSN
Contact The Gross Law Firm by June 3, 2025 Deadline to Join Class Action Against Cerevel Therapeutics Holdings, Inc.(ABBV) - TradingView
AbbVie Stock Down Around 13% in 3 Months: Time to Buy the Dip? - Yahoo Finance
AbbVie: Fairly Valued, But Lacking A Spark - Seeking Alpha
Cancer Therapeutics Market Is Booming So Rapidly 2025-2032 - openPR.com
Class Action Filed Against Cerevel Therapeutics Holdings, Inc. (ABBV) Seeking Recovery for InvestorsContact The Gross Law Firm - marketscreener.com
Drug Device Combination Products Market Analysis Report 2025-2030: Discover the Latest Advances and Opportunities - GlobeNewswire Inc.
AbbVie Inc. (ABBV)’s Pipeline Advances with Temab-A and ABBV-706, Shares Flat - Yahoo Finance
Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies - marketscreener.com
CERE DEADLINE: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - GlobeNewswire Inc.
AbbVie (NYSE:ABBV) Showcases Promising Phase 1 ADC Results For Advanced Cancers - Yahoo Finance
Bearish Sentiment and Increased Put Activity for AbbVie (ABBV) | - GuruFocus
AbbVie put volume heavy and directionally bearish - TipRanks
Sarah Cannon Research Institute Announces Strategic Alliance With AbbVie to Advance Novel Cancer Therapies - BioSpace
Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? - sharewise
Targeted Drug Delivery Research Business Analysis Report 2024-2030 with Focus on 30+ Key Players Such as AbbVie, Amgen, AstraZeneca, Becton Dickinson and Co, & Bristol-Myers Squibb - GlobeNewswire
AbbVie’s Allergan cuts over 200 staff after botched marketing campaign - PharmaLive
AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit - MSN
AbbVie To Present Cancer Trial Data At Upcoming ASCO Event - Benzinga
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio - Investing News Network
AbbVie Features New Data Across Difficult-to-Treat Solid Tumors and Blood Cancers at ASCO 2025, Highlighting Breadth and Depth of its Oncology Portfolio | ABBV Stock News - GuruFocus
Tissue Engineering Market Generated Opportunities, Future - openPR.com
Prurigo Nodularis Market - GlobeNewswire Inc.
AbbVie’s SWOT analysis: biopharma giant faces pipeline challenges amid stock growth - Investing.com
Precision immunology Market Growth in Future Scope 2025-2032 | - openPR.com
Immunomodulatory Drugs Market in 2025 Detailed Study Analysis | - openPR.com
Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie - insights.citeline.com
CERE DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Cerevel Therapeutics Holdings, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 3 Deadline in Securities Class Action - GlobeNewswire Inc.
AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer - MSN
Key Drivers Behind AbbVie’s (ABBV) Performance - Insider Monkey
Levi & Korsinsky Notifies Cerevel Therapeutics Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineABBV - marketscreener.com
AbbVie (NYSE:ABBV) Faces Legal Scrutiny Over Merger With Cerevel - Yahoo Finance
AbbVie and U of T Mississauga's SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient - Investing News Network
AbbVie Secures Legal Victory Over Allergan Share Dispute - USA Herald
Interleukin Inhibitors Market Detailed In New Research Report - openPR.com
AbbVie (ABBV) has a Stable and Highly Profitable Business Model - Insider Monkey
Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change - Pharma Voice
Cerevel Therapeutics Holdings, Inc. Sued for Securities Law ViolationsContact The Gross Law Firm Before June 3, 2025 to Discuss Your RightsABBV - marketscreener.com
AbbVie Gets Victory In Allergan Shareholder Suit Upheld - Law360
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.75%
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):